{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:07:21Z","timestamp":1793390841849,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-04091-6","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:42:53Z","timestamp":1763545373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative effects of empagliflozin and metformin on metabolic dysfunction in polycystic ovary syndrome, a double blinded randomized control feasibility trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Hina","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Arsalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammara","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Hatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Wasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajiha","family":"Omair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"13","key":"4091_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.874914","volume":"18","author":"LH Zeng","year":"2022","unstructured":"Zeng LH, Rana S, Hussain L, Asif M, Mehmood MH, Imran I, et al. Polycystic ovary syndrome: a disorder of reproductive age, its pathogenesis, and a discussion on the emerging role of herbal remedies. Front Pharmacol. 2022;18(13):874914.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4091_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.37745\/ejbmsr.2013\/vol11n15791","volume":"11","author":"S Karkera","year":"2023","unstructured":"Karkera S, Agard E, Sankova L. The clinical manifestations of polycystic ovary syndrome (PCOS) and the treatment options. European Journal of Biology and Medical Science Research. 2023;11(1):57\u201391.","journal-title":"European Journal of Biology and Medical Science Research"},{"issue":"1","key":"4091_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/humrep\/dead241","volume":"39","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang J, Wang S. Global, regional, and national burden of infertility attributable to PCOS, 1990\u20132019. Hum Reprod. 2024;39(1):108\u201318.","journal-title":"Hum Reprod"},{"issue":"1","key":"4091_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.53560\/PPASB(59-1)703","volume":"59","author":"S Zulfiqar","year":"2022","unstructured":"Zulfiqar S, Tahir S, Gulraiz S, Razzaq MA, Abid A, Shahid T, et al. Investigation of prevalence and awareness of polycystic ovary syndrome among Pakistani females: polycystic ovary syndrome in Pakistani women. Proceedings of the Pakistan Academy of Sciences: B Life and Environmental Sciences. 2022;59(1):77\u201383.","journal-title":"Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences"},{"key":"4091_CR5","unstructured":"Chatterjee M, Levine R, Rao-Seshadri S, Murthy N. Better Reproductive Health for Poor Women in South Asia"},{"key":"4091_CR6","unstructured":"National Research Council, Board on Children, Youth, Committee on Oral Health Access to Services. Improving access to oral health care for vulnerable and underserved populations. National Academies Press. 2012."},{"issue":"8","key":"4091_CR7","first-page":"89","volume":"26","author":"AT Ali","year":"2022","unstructured":"Ali AT, Al-Ani O, Al-Ani F, Guidozzi F. Polycystic ovary syndrome and metabolic disorders: a review of the literature. Afr J Reprod Health. 2022;26(8):89\u201399.","journal-title":"Afr J Reprod Health"},{"issue":"86","key":"4091_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.metabol.2017.09.016","volume":"1","author":"P Anagnostis","year":"2018","unstructured":"Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;1(86):33\u201343.","journal-title":"Metabolism"},{"issue":"5","key":"4091_CR9","first-page":"263","volume":"13","author":"K Beltadze","year":"2015","unstructured":"Beltadze K, Barbakadze L. Ovarian reserve in women of late reproductive age by the method of treatment of PCOS. Iran J Reprod Med. 2015;13(5):263.","journal-title":"Iran J Reprod Med"},{"key":"4091_CR10","doi-asserted-by":"crossref","unstructured":"Olanrewaju OA, Sheeba F, Kumar A, Ahmad S, Blank N, Kumari R, Kumari K, Salame T, Khalid A, Varrassi G, Khatri M. Novel therapies in diabetes: a comprehensive narrative review of GLP-1 receptor agonists, SGLT2 inhibitors, and beyond. Cureus. 2023;15(12).","DOI":"10.7759\/cureus.51151"},{"key":"4091_CR11","unstructured":"World Health Organization: https:\/\/www.who.int\/data\/maternal-newborn-child-adolescent-ageing\/indicator-explorer-new\/mca\/women-of-reproductive-age-(15-49-years)-population-(thousands) [Accessed Date: 22nd April 2025]."},{"key":"4091_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM -Sponsored PCOS consensus workshop group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM -Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long -term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41\u20137.","journal-title":"Hum Reprod"},{"key":"4091_CR13","volume-title":"Hefni DH. Assessing the effectiveness of an obesity-prevention intervention to improve healthy lifestyle among Saudi school girls aged 9 to 16: a feasibility study. University of Salford (United Kingdom); 2017.","year":"2017","unstructured":"Medical Research Council (MRC) Framework. https:\/\/1library.net\/article\/assessing-feasibility-medical-research-council-mrc-framework.zw598g7z"},{"issue":"4","key":"4091_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","volume":"13","author":"R Deswal","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261\u201371.","journal-title":"J Hum Reprod Sci"},{"issue":"2","key":"4091_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020583","volume":"23","author":"HM Sadeghi","year":"2022","unstructured":"Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4091_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061113","volume":"13","author":"JP Christ","year":"2023","unstructured":"Christ JP, Cedars MI. Current guidelines for diagnosing PCOS. Diagnostics. 2023;13(6):1113.","journal-title":"Diagnostics"},{"key":"4091_CR17","unstructured":"Tatkare HU. The Relationship Between Obesity, Visceral Adiposity and Polycystic Ovarian Syndrome in Adult Women of Childbearing Age (Master's thesis, California Baptist University). 2021."},{"issue":"4","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.23736\/S0026-4946.20.05861-2","volume":"72","author":"ME Street","year":"2020","unstructured":"Street ME, Cirillo F, Catellani C, Dauriz M, Lazzeroni P, Sartori C, et al. Current treatment for polycystic ovary syndrome: focus on adolescence. Minerva Pediatr. 2020;72(4):288\u2013311.","journal-title":"Minerva Pediatr"},{"issue":"10","key":"4091_CR19","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/humrep\/des232","volume":"27","author":"BO Yildiz","year":"2012","unstructured":"Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067\u201373.","journal-title":"Hum Reprod"},{"issue":"Supplement_1","key":"4091_CR20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc23-Srev","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Summary of revisions: standards of care in diabetes\u20142023. Diabetes Care. 2023;46(Supplement_1):S5\u20139.","journal-title":"Diabetes Care"},{"issue":"22","key":"4091_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"4091_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2337\/dc15-2237","volume":"39","author":"RJ Smith","year":"2016","unstructured":"Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39(5):738\u201342.","journal-title":"Diabetes Care"},{"issue":"4","key":"4091_CR23","first-page":"213","volume":"16","author":"S Choobkar","year":"2024","unstructured":"Choobkar S, Alilou M, Mahmoudvand G, Karimi Rouzbahani A. Evaluation of the effects of Empagliflozin on serum levels of triglycerides and cholesterol in patients with type 2 diabetes mellitus and hypertriglyceridemia: a prospective study. Iran J Diabetes Obes. 2024;16(4):213\u201320.","journal-title":"Iran J Diabetes Obes"},{"issue":"10","key":"4091_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"6","key":"4091_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","volume":"90","author":"Z Javed","year":"2019","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol. 2019;90(6):805\u201313.","journal-title":"Clin Endocrinol"},{"key":"4091_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S97619","author":"VP Sanon","year":"2017","unstructured":"Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Ther Clin Risk Manag. 2017. https:\/\/doi.org\/10.2147\/TCRM.S97619.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"4091_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052576","volume":"22","author":"JE Pruett","year":"2021","unstructured":"Pruett JE, Torres Fernandez ED, Everman SJ, Vinson RM, Davenport K, Logan MK, et al. Impact of SGLT-2 inhibition on cardiometabolic abnormalities in a rat model of polycystic ovary syndrome. Int J Mol Sci. 2021;22(5):2576.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4091_CR28","doi-asserted-by":"publisher","DOI":"10.59299\/2537-0928.1025","volume":"6","author":"DSE El Gohary","year":"2023","unstructured":"El Gohary DSE, Ismail MM, Elbohoty SB. Effect of Empagliflozin Metformin with Clomiphene Citrate versus Metformin with Clomiphene Citrate on cases of Polycystic Ovary Syndrome. Journal of Medicine in Scientific Research. 2023;6(2):3.","journal-title":"Journal of Medicine in Scientific Research"},{"key":"4091_CR29","unstructured":"Pruett JE. Impact of Sodium-Glucose Cotransporter-2 Inhibition on the Cardiometabolic Profile of Polycystic Ovary Syndrome (Doctoral dissertation, The University of Mississippi Medical Center). 2022."},{"issue":"4","key":"4091_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041056","volume":"13","author":"R Porth","year":"2024","unstructured":"Porth R, Oelerich K, Sivanandy MS. The role of sodium-glucose cotransporter-2 inhibitors in the treatment of polycystic ovary syndrome: a review. J Clin Med. 2024;13(4):1056.","journal-title":"J Clin Med"},{"issue":"4","key":"4091_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pathophysiology31040041","volume":"31","author":"D Rakic","year":"2024","unstructured":"Rakic D, Jakovljevic V, Zivkovic V, Jakovljevic Uzelac J, Jovic N, Muric M, et al. Multiple benefits of Empagliflozin in PCOS: evidence from a preclinical rat model. Pathophysiology. 2024;31(4):559\u201382.","journal-title":"Pathophysiology"},{"issue":"2","key":"4091_CR32","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac191","volume":"7","author":"JE Pruett","year":"2023","unstructured":"Pruett JE, Lirette ST, Romero DG, Yanes Cardozo LL. Sodium-glucose cotransporter-2 inhibition benefits in cardiorenal risk in men and women. J Endocr Soc. 2023;7(2):bvac191.","journal-title":"J Endocr Soc"},{"issue":"26","key":"4091_CR33","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.2174\/138161209789058101","volume":"15","author":"AB Motta","year":"2009","unstructured":"Motta AB. Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome. Curr Pharm Des. 2009;15(26):3074\u20137.","journal-title":"Curr Pharm Des"},{"key":"4091_CR34","unstructured":"Genazzani AD, Ricchieri F, Prati, AL, Chierchia E, Rattighieri ER, Bosco GI, ... & Santagni SU. PCOS and metformin: from pharmacology to clinical use for women\u2019s health. Trial. 2012: 12: 14."},{"issue":"9","key":"4091_CR35","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"CJ Bailey","year":"2017","unstructured":"Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566\u201376.","journal-title":"Diabetologia"},{"issue":"1","key":"4091_CR36","first-page":"25","volume":"37","author":"MO Weickert","year":"2012","unstructured":"Weickert MO, Hodges P, Tan BK, Randeva HS. Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. Minerva Endocrinol. 2012;37(1):25\u201340.","journal-title":"Minerva Endocrinol"},{"issue":"2","key":"4091_CR37","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/ejendo\/lvad098","volume":"189","author":"J Melin","year":"2023","unstructured":"Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol. 2023;189(2):S38\u201364.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"4091_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123294","volume":"10","author":"J Forycka","year":"2022","unstructured":"Forycka J, Hajdys J, Krzemi\u0144ska J, Wilczopolski P, Wronka M, M\u0142ynarska E, et al. New insights into the use of Empagliflozin\u2014a comprehensive review. Biomedicines. 2022;10(12):3294.","journal-title":"Biomedicines"},{"key":"4091_CR39","doi-asserted-by":"crossref","unstructured":"Sinha T, Gul U, Babar NN, Israr F, Butt AA, Chaudhari SS, ... & Amin A. The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis. Cureus. 2024; 16(9).","DOI":"10.7759\/cureus.69711"},{"issue":"10","key":"4091_CR40","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","volume":"106","author":"KE Elkind-Hirsch","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(10):3019\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4091_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83820-7","volume":"15","author":"M Sanjari","year":"2025","unstructured":"Sanjari M, Hadavizadeh M, Sadeghi N, Naghibzadeh-Tahami A. Effect of empagliflozin on weight in patients with prediabetes and diabetes. Sci Rep. 2025;15(1):118.","journal-title":"Sci Rep"},{"issue":"6","key":"4091_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3682","volume":"39","author":"IG Lempesis","year":"2023","unstructured":"Lempesis IG, Apple SJ, Duarte G, Palaiodimos L, Kalaitzopoulos DR, Dalamaga M, et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes Metab Res Rev. 2023;39(6):e3682.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"4091_CR43","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"4091_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.830401","volume":"13","author":"B Sinha","year":"2022","unstructured":"Sinha B, Ghosal S. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors on metabolic parameters in patients with polycystic ovary syndrome. Front Endocrinol. 2022;13:830401.","journal-title":"Front Endocrinol"},{"issue":"11","key":"4091_CR45","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4091_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"AA Tahrani","year":"2013","unstructured":"Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4091_CR47","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.fertnstert.2006.04.011","volume":"86","author":"A Dunaif","year":"2006","unstructured":"Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006;86:S13\u20134.","journal-title":"Fertil Steril"},{"issue":"9","key":"4091_CR48","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstr\u00e5le","year":"2014","unstructured":"Ridderstr\u00e5le M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomized, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691\u2013700.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4091_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","volume":"375","author":"CR McCartney","year":"2016","unstructured":"McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54\u201364.","journal-title":"N Engl J Med"},{"issue":"5","key":"4091_CR50","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1007\/s00210-023-02826-6","volume":"397","author":"MM Elseweidy","year":"2024","unstructured":"Elseweidy MM, Ali AEM, Hassanin SM, Mahmoud YK. Empagliflozin ameliorates liver fibrosis in NASH rat model by targeting hepatic NF-\u03baB\/SOX9\/OPN signaling and osteocalcin level. Naunyn-Schmiedebergs Arch Pharmacol. 2024;397(5):3449\u201359.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"4091_CR51","doi-asserted-by":"crossref","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, ... & Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016; 22: 1\u2013203.","DOI":"10.4158\/EP161365.GL"},{"key":"4091_CR52","unstructured":"Hossain A, Banu H, Morshed MS, Afrine S & Hasanat MA. Short-term and low-dose liraglutide plus metformin decreased body mass index and insulin resistance more than metformin alone in obese women with polycystic ovary syndrome: An open-label randomized controlled study."},{"issue":"4","key":"4091_CR53","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3081","volume":"11","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Exp Ther Med. 2016;11(4):1.","journal-title":"Exp Ther Med"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04091-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:02:51Z","timestamp":1763550171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-04091-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04091-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the SINA Ethical Review Board (approval number ERB0000013\/03\u201323). Written and verbal informed consent was obtained from all participants after they discussed all the parameters and aspects of the research, highlighting the right to leave at any time during the trial and to voluntarily participate, and the clinical trial registration number was NCT06140108 in\n                      \n                      registration date 11th of November, 2023. Recruitment of the participants started at 15th of November 2023 and trial started in December 2023 and ended in June 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors read and agreed to publish this material.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"565"}}